hcc
No description yet: the sentence for this tag has not been written. 8 records carry it: 8 people.
Related tags
8 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Andrew X. Zhu Hepatobiliary medical oncologist and trial lead Oncologist who led REACH-2, the first positive biomarker-selected trial in liver cancer, which established ramucirumab for patients with a high alpha-fetoprotein level. | Advanced hepatocellular carcinoma, Hepatocellular carcinoma, Intrahepatic cholangiocarcinoma | none | biliary, trialist | ||
Ann-Lii Cheng Distinguished Professor and Director, National Taiwan University Cancer Center · National Taiwan University Hospital Taiwanese oncologist who led the Asia-Pacific sorafenib trial and co-led IMbrave150, the immunotherapy standard for liver cancer. | Hepatocellular carcinoma | none | immunotherapy, asia | ||
Ghassan K. Abou-Alfa Attending Physician, Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center Led HIMALAYA and ClarIDHy, which gave liver cancer a dual-immunotherapy option and biliary cancer its first targeted drug. | Hepatocellular carcinoma, Biliary tract cancer | none | biliary, trialist | ||
Jordi Bruix Hepatologist, Barcelona Clinic Liver Cancer group, Hospital Clínic de Barcelona · Hospital Clínic de Barcelona / IDIBAPS Barcelona liver specialist who co-created the BCLC staging system used worldwide to decide how liver cancer is treated, and led STORM, which showed adjuvant sorafenib does not help after curative treatment. | Early hepatocellular carcinoma, Advanced hepatocellular carcinoma, Hepatocellular carcinoma | none | trialist | ||
Josep M. Llovet Director, Liver Cancer Program, Icahn School of Medicine at Mount Sinai; Professor, University of Barcelona · The Mount Sinai Hospital / Tisch Cancer Institute Led SHARP, which made sorafenib the first systemic therapy for liver cancer, and created the BCLC staging system. | Hepatocellular carcinoma | none | staging, trialist, clinician-scientist | ||
Masatoshi Kudo Professor and Chairman, Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine · Kindai University Faculty of Medicine and Hospital Japanese hepatologist who led REFLECT, the trial that made lenvatinib a first-line option for liver cancer. | Hepatocellular carcinoma | none | japan, trialist | ||
Richard S. Finn Professor of Medicine, UCLA Jonsson Comprehensive Cancer Center · UCLA Jonsson Comprehensive Cancer Center Led PALOMA-2, which made palbociclib a first-line breast cancer drug, and IMbrave150, which made immunotherapy the standard for liver cancer. | HR-positive / HER2-negative breast cancer, Hepatocellular carcinoma | none | breast, trialist | ||
Robin Kate Kelley Gastrointestinal oncologist, UCSF Helen Diller Family Comprehensive Cancer Center · UCSF Helen Diller Family Comprehensive Cancer Center San Francisco oncologist who was lead author of KEYNOTE-966, which showed that adding pembrolizumab to gemcitabine and cisplatin helps people with advanced bile duct cancer live longer. | Intrahepatic cholangiocarcinoma, Biliary tract cancer, Hepatocellular carcinoma | none | biliary, immunotherapy, trialist |
